Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Eli Lilly Stock Is Down Today

By Prosper Junior Bakiny - Oct 27, 2020 at 12:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's third-quarter financial results did not impress investors.

What happened? 

Shares of Eli Lilly ( LLY -2.67% ) were dropping sharply on Tuesday, down by 5.3% as of 12:12 p.m. EDT after falling by as much as 6.2% earlier. Investors are reacting to the drugmaker's disappointing third-quarter earnings report, which it released before the market opened today. 

So what

During its third quarter, Eli Lilly's revenue came in at $5.7 billion. While that was a 5% increase from last year's third quarter, it also came in short of the $5.91 billion analysts were expecting on average. This was despite several of the company's products performing well during the quarter. For instance, sales of diabetes medicine Trulicity increased by 9% year over year to $1.11 billion, while revenue from plaque psoriasis treatment Taltz soared by 34% to $454.5 million.

Five downward-bound arrows on a blackboard.

Image source: Getty Images.

Alimta, a cancer medicine, saw its sales grow by 14% year over year to $578 million.

Adjusted earnings per share were $1.54, compared with $1.48 during the year-ago period. But again, the pharma giant came up short of expectations on the bottom line; on average, analysts expected the company to deliver adjusted EPS of $1.71.

Now what

Eli Lilly performed well during the first half of the year, but its shares have been dropping since late July. After today's decline, the stock is up by only 2.1% year to date, compared with gains of 5.4% for the S&P 500. Despite its disappointing earnings report, it may be worth it for long-term investors to consider scooping up shares of this pharma stock, particularly at current levels. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$248.04 (-2.67%) $-6.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.